A phase II trial of Afimoxifene (4-hydroxytamoxifen gel) for cyclical mastalgia in premenopausal women

scientific article

A phase II trial of Afimoxifene (4-hydroxytamoxifen gel) for cyclical mastalgia in premenopausal women is …
instance of (P31):
scholarly articleQ13442814

External links are
P6179Dimensions Publication ID1005669259
P356DOI10.1007/S10549-007-9507-X
P698PubMed publication ID17351746

P2093author name stringAmit Goyal
Elisabeth Le Nestour
Katharine O'Connell
Robert Mansel
Afimoxifene (4-OHT) Breast Pain Research Group
Valérie Masini-Etévé
P433issue3
P407language of work or nameEnglishQ1860
P921main subject(Z)-4-hydroxytamoxifenQ4689254
phase II clinical trialQ42824440
P304page(s)389-397
P577publication date2007-03-10
P1433published inBreast Cancer Research and TreatmentQ326085
P1476titleA phase II trial of Afimoxifene (4-hydroxytamoxifen gel) for cyclical mastalgia in premenopausal women
P478volume106

Reverse relations

cites work (P2860)
Q33914381A randomized phase II presurgical trial of transdermal 4-hydroxytamoxifen gel versus oral tamoxifen in women with ductal carcinoma in situ of the breast
Q41726822Addressing barriers to uptake of breast cancer chemoprevention for patients and providers
Q37014147Boron-Based 4-Hydroxytamoxifen Bioisosteres for Treatment of de Novo Tamoxifen Resistant Breast Cancer
Q35768721Boronic prodrug of 4-hydroxytamoxifen is more efficacious than tamoxifen with enhanced bioavailability independent of CYP2D6 status
Q26825584Development of new estrogen receptor-targeting therapeutic agents for tamoxifen-resistant breast cancer
Q38792320Estrogen Receptors and Signaling in Fibroids: Role in Pathobiology and Therapeutic Implications.
Q37355945In vitro human skin permeation of endoxifen: potential for local transdermal therapy for primary prevention and carcinoma in situ of the breast
Q53280631Local transdermal therapy to the breast for breast cancer prevention and DCIS therapy: preclinical and clinical evaluation.
Q26825692Nuclear receptors and their selective pharmacologic modulators
Q33739214Oral low dose and topical tamoxifen for breast cancer prevention: modern approaches for an old drug.
Q57487446Selective Estrogen Receptor Modulators
Q26739969Tamoxifen Resistance: Emerging Molecular Targets

Search more.